{"entity":{"id":"nct04014530","kind":"trial","name":"Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study","aka":["ATAPEMBRO"],"tldr":"A phase 1/2 trial of pembrolizumab in colorectal cancer, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), now recruiting.","summary":"Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study is a phase 1/2, interventional study registered as NCT04014530 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), with a registry enrolment figure of 47 participants, started 2019-08-01 and due to reach its primary completion in 2023-06-01. Interventions recorded: Ataluren + Pembrolizumab. Conditions listed: Colorectal Cancer; Endometrium Cancer. Primary outcome: Incidence of treatment-Emergent Adverse Event and the determination of the maximum tolerable dose of Ataluren.; Objective response rate. Colorectal eligibility wording from the registry: \"inaccessible by colonoscopy or CT-guided approaches or due to safety concerns) may submit an archived specimen only upon agreement from the Sponsor\". Sites: Netherlands. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04014530","url":"https://clinicaltrials.gov/study/NCT04014530"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04014530","phase":"1/2","setting":"Study of Pembrolizumab Combined With Ataluren In Patients With Metastatic pMMR and dMMR Colorectal Adenocarcinomas or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","enrolled":47,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04014530/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}